Nuzyra™ (omadacycline) – New drug approval
October 2, 2018 - Paratek Pharmaceuticals announced the FDA approval of Nuzyra (omadacycline), for the treatment of adult patients with the following infections caused by susceptible microorganisms: community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).
Top